{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "POXEL S.A.  EO -,02", "longName": "Poxel S.A.", "messageBoardId": "finmb_109129442", "market": "dr_market", "marketState": "REGULAR", "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -1.02, "sharesOutstanding": 31883600, "bookValue": -0.124, "fiftyDayAverage": 0.69744, "fiftyDayAverageChange": -0.056440055, "fiftyDayAverageChangePercent": -0.0809246, "twoHundredDayAverage": 1.272835, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "esgPopulated": false, "regularMarketChangePercent": 0.7861628, "regularMarketPrice": 0.641, "regularMarketChange": 0.004999995, "regularMarketTime": 1683895501, "regularMarketDayHigh": 0.645, "regularMarketDayRange": "0.633 - 0.645", "regularMarketDayLow": 0.633, "regularMarketVolume": 380, "regularMarketPreviousClose": 0.636, "bid": 0.643, "ask": 0.654, "bidSize": 1316, "askSize": 1304, "fullExchangeName": "Frankfurt", "financialCurrency": "EUR", "regularMarketOpen": 0.645, "averageDailyVolume3Month": 299, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 0.037999988, "fiftyTwoWeekLowChangePercent": 0.063018225, "fiftyTwoWeekRange": "0.603 - 2.705", "fiftyTwoWeekHighChange": -2.064, "fiftyTwoWeekHighChangePercent": -0.7630314, "fiftyTwoWeekLow": 0.603, "fiftyTwoWeekHigh": 2.705, "twoHundredDayAverageChange": -0.63183504, "twoHundredDayAverageChangePercent": -0.4963998, "marketCap": 20437386, "priceToBook": -5.169355, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "firstTradeDateMilliseconds": 1423724400000, "priceHint": 4, "symbol": "7PO.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Immeuble Le Sunway", "address2": "259-261 Avenue Jean JaurEs", "city": "Lyon", "zip": "69007", "country": "France", "phone": "33 4 37 37 20 10", "fax": "33 4 37 70 88 15", "website": "https://www.poxelpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.", "fullTimeEmployees": 55, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Kuhn M.B.A., Pharm.D., Pharm D MBA", "title": "Co-Founder, CEO & Director", "fiscalYear": 2020, "totalPay": {"raw": 398542, "fmt": "398.54k", "longFmt": "398,542"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. S\u00e9bastien  Bolze Ph.D., Pharm.D., Pharm D Ph.D.", "title": "Co-Founder, COO & Exec. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Pascale  Fouqueray-Grellier M.D., Ph.D.", "title": "Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sophie  Hallakou-Bozec Ph.D.", "title": "Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David E. Moller M.D.", "title": "Exec. VP & Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Woo M.B.A.", "title": "Sr. VP of Investor Relations, Corp. Communications & PR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Quentin  Durand", "title": "Exec. VP, Chief Legal Officer & Head of CSR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sylvie  Bertrand", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Noah D. Beerman MBA", "age": 60, "title": "Exec. VP of Bus. Devel. & Pres of US Operations", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400}}], "error": null}}